Objective: The most common and deadliest urological cancer is clear cell Renal Cell Carcinoma (ccRCC). ccRCC is characterized by striking reorganization of both carbohydrate and lipid metabolism. It was recently demonstrated that lipid remodeling enzyme Membrane-Bound O-Acyltransferase 7 (MBOAT7) that generates phosphatidylinositol (PI) is important for the ccRCC progression. However, whether MBOAT7-driven PI remodeling is associated with other metabolic alterations commonly found in ccRCC is poorly understood.
Introduction
The most prevalent and devastating kidney cancer is clear cell Renal cell carcinoma (ccRCC) [1] . ccRCC has a large lipid rich tumor component compared to other solid tumors [2] [3] [4] . Several studies have demonstrated a lipid droplet protein (PLIN2) is a biomarker of ccRCC tumors [4, 5] . Past studies in other models have shown, signaling phospholipids such as phosphatidylinositol and phosphoinositides (PIPs) are critical for life [6, 7] . Previous work has demonstrated that PI3K and PIP3,4,5 is critical for Aldolase mobilization to facilitate glycolysis [8] . This work demonstrates a clear link between phosphoinositide signaling and glycolytic regulation.
Similar to many other cancers, ccRCC is characterized by high glycolytic rates that support Warburg metabolism [9] . With dependency on glycolysis, ccRCC upregulates glucose transporter GLUT1, increases the rate-limiting hexokinase II (HK2), and several other members of glycolysis through hypoxia inducible factors (HIF). Although it is appreciated that glucose metabolism is altered in ccRCC renal physiology upon transformation, the mechanisms of modulating glucose metabolism following transformation is less understood [10] .
Furthermore, our recent work demonstrated arachidonic acid-containing phosphatidylinositol (AA-PI) and Lands' Cycle remodeling enzyme, MBOAT7, is important for tumor PI generation, downstream signaling and tumor formation (Neumann et al. 2020. Mol. Metab. In Press). However, the mechanism by which MBOAT7 altered tumor biology was not completely understood. MBOAT7 alters specifically PI and is not promiscuous across other phospholipid species [11, 12] . MBOAT7 knockout has been shown to decrease phosphoinositide levels in multiple tissues through decreasing substrate availability [12, 13] . A key ccRCC cell line used in this study is 786-O; this line has a known PTEN mutation which confers a more aggressive and metabolically active phenotype in vivo and in vitro [14, 15] . Although lipid metabolism and ccRCC has recently been studied [16] , little has been done to address the relationship between lipid metabolism and glycolysis. Here we demonstrate that MBOAT7 deficiency decreases glycolysis through Aldolase and HK2. MBOAT7 loss of function reduces mitochondrial respiration and ATP production, which results in a dramatic increased survival in vivo in the 786-O xenograft model. These data support the hypothesis that limiting phosphoinositide phospholipids reduces glycolysis and may hold therapeutic promise. 
Methods

Cell Lines and Cell
Western Blot Analysis.
Cell tissue lysates were generated using a modified RIPA buffer and western blotting was performed following the previously described methods [17] . Antibodies used are available through Sigma Aldrich or Cell Signaling with the corresponding product numbers in Table 2 . 
Seahorse Metabolic Fitness
Results
Loss of MBOAT7 correlates with a decrease in glucose consumption and glycolytic gene expression.
To study the role of MBOAT7 and PI metabolism on glycolysis, we utilized previously published MBOAT7 deficient ccRCC Caki-1 and 786-O cell. We observed that with MBOAT7 loss of function, the acidification of media occurs more slowly compared to wild-type ( Figure 1A) . Utilizing a previously described RNAseq dataset in the Caki-1 cell line (GSE131881), we see that MBOAT7 deficiency leads to a significant reduction in the glycolytic gene set after gene set enrichment analysis (GSEA) ( Figure 1B) . Looking specifically at the initial steps of glycolysis, there is a reduction in the hexokinase 2 (HK2), glucose-6-phosphate isomerase (GPI), and phosphofructokinase (PFKP) with MBOAT7 loss of function in the RNAseq dataset ( Figure 1C) . In vitro experiments, we see that MBOAT7 deficiency leads to a decrease in glucose consumption and lactate production ( Figure 1D) , consistent with decreased glycolysis.
MBOAT7 deficiency reduces pyruvate and several key glycolytic enzymes in HK2
and ALDOC. We pursued targeted mass spectrometry for the glycolytic intermediates in the Caki-1 model following high glucose supplementation for 1 hour. Dihydroxyacetone and pyruvate, an intermediate and product of glycolysis (Figure 2A ) demonstrates a significant reduction following MBOAT7 loss of function, which corresponds with the loss of gene expression in HK2 and ALDOC ( Figure 2B) . To validate the reduction in HK2 expression, we performed western blotting and see that HK2 protein abundance decreases with MBOAT7 deficiency in the Caki-1 and 786-O models ( Figure 2C) . These data suggest alterations in glycolysis and metabolic fitness with MBOAT7 deficiency.
MBOAT7 loss of function reduces glycolysis and metabolic fitness. To assess glucose metabolism, we utilized the Seahorse Metabolic Stress Tests. Oxygen consumption rate (OCR) is directly related to ATP production through the electron transport chain. In our initial tests with glucose, MBOAT7 deficient Caki-1 cells have a reduced basal and maximal respiration ( Figure 3A) . Our findings are validated in the 786-O RCC model that basal and maximal respiration are reduced with the loss of MBOAT7 ( Figure 3B) . MBOAT7 deficiency significantly reduces ATP production in the Caki-1 and 786-O cell models (Figure 3C,D) . To assess glucose utilization, we performed glycolysis stress test in the presence of base media alone, which demonstrated a reduction in maximum glycolysis with MBOAT7 deficiency (Figure 3E ). This significant reduction in glycolysis could be rescued with pyruvate supplementation into the media ( Figure 3F ).
MBOAT7 loss of function decreases in vivo tumor volume and glycolysis.
To test the overall tumor growth, MBOAT7 wild type or deficient 786-O cells were injected into the flanks of Nod SCID Gamma (NSG) mice. In this experiment, we see an increased in vivo overall survival with MBOAT7 loss of function ( Figure 4A) . Accordingly, the tumor volume at end-point for all animals is substantially reduced with MBOAT7 deficiency ( Figure 4B ). To confirm these data, we utilized histology and immunohistochemistry to stain for the H&E (architecture), Ki67 (cell division), and Hexokinase 2 (glycolysis) ( Figure 4C ). The quantification of tumor staining with or without MBOAT7 demonstrates a reduction in Ki67 + staining per field and trending reductions in HK2 staining ( Figure   4D ). The in vivo gene expression shows a significant reduction in the rate-limiting glycolytic pathway member, HK2, within MBOAT7 deficient tumors ( Figure 4E ). Other metabolic regulators were assessed in these tumors such as CPT1A, PPARA, and PPARG (Supplementary). Additionally, we also see trending increases in Trichrome fibrosis staining in the MBOAT7 wild-type tumors (Supplementary) . Mechanistically, MBOAT7 deficiency leads to a decrease in in vivo P-S6K and P-ERK signaling, while maintaining reduced HK2 protein abundance ( Figure 4F ).
Discussion
A hallmark of many cancers including kidney cancer is the unrelenting metabolic adaptation and glycolysis that occurs. To meet metabolic demand, tumor metabolism increases glycolysis, which provides a relatively inefficient ATP production. The Warburg effect in full force leads to increased glycolysis and substrate influx to help fuel the increased anabolism for cell division and proliferation. Glycolytic gene expression can be altered through multiple mechanisms including HIF and mTORC [18] [19] [20] [21] , the continued signaling through these nodes can lead to increases in glycolytic enzymatic intermediates. Others have shown PI3K and subsequent product (PIP3,4,5) is critical for the downstream signaling and increased glycolytic activity through mTORC1/S6K [8, 15] .
In our previous study that identified MBOAT7's potential role in cancer, we Interestingly, previous studies have shown that PTEN mutations increase basal glycolysis and cell growth of mouse embryonic fibroblast (MEF) [22] . For the first time, this study demonstrates that limiting upstream PI production through MBOAT7 can limit glycolysis, metabolic fitness, and in vivo tumor growth regardless of PTEN status. This study gives more evidence that PI metabolism helps regulate glycolysis. This also provides rationale for several future studies including assessing MBOAT7/AA-PI role in other PI3K/mTORC1 dependent cancers, in vivo MBOAT7 knockdown interventional study with PTEN mut /PI3K/mTORC1 active cancer models, developing small molecule inhibitors towards MBOAT7, and determining the role for Lands' Cycle in cancer progression. 
